FindTrial
Sign In

The cytokines in predicting ECMO in patients with cardiogenic shock due to acute myocardial infarction

Prognostic value of cytokines kinetics in predicting ECMO in patients with cardiogenic shock due to acute myocardial infarction

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200062790
Enrollment
Unknown
Registered
2022-08-19
Start date
2022-09-01
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cardiogenic shock due to acute myocardial infarction

Interventions

ECMO treatment group:ECMO

Sponsors

Southern Medical University (the First people’s hospital of Shunde)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Voluntary signing of informed consent; 2. Age >= 18 years old; 3. Patients who have indications for ECMO support and need ECMO support according to the judgment of clinicians.

Exclusion criteria

Exclusion criteria: 1. Pregnancy or lactation; 2. Advanced tumor patients; 3. Solid organ or bone marrow transplant recipients; 4. Suffering from autoimmune diseases or immunodeficiency; 5. Receiving cytokine or cytokine inhibition therapy; 6. Patients receiving long-term hemodialysis or peritoneal dialysis; 7. Patients with SIRS caused by other reasons; 8. Patients who died within 24 hours.

Design outcomes

Primary

MeasureTime frame
cytokines level;—

Countries

China

Contacts

Public ContactZhen Chen
179738867@qq.com+86 15622168504

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026